Anti-angiogenic therapy in the setting of TACE: an elusive synergy?

Affiliations

¹ Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, FC10.3064, Houston, TX 77030, USA. Electronic address: akaseb@mdanderson.org.

Comment

Bruno C Odisio et al. Lancet Gastroenterol Hepatol. 2018 Jan.

. 2018 Jan;3(1):5-6.

doi: 10.1016/S2468-1253(17)30324-2. Epub 2017 Oct 4.

¹ Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, FC10.3064, Houston, TX 77030, USA. Electronic address: akaseb@mdanderson.org.

No abstract available

Comment on

Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Kudo M, Cheng AL, Park JW, Park JH, Liang PC, Hidaka H, Izumi N, Heo J, Lee YJ, Sheen IS, Chiu CF, Arioka H, Morita S, Arai Y. Kudo M, et al. Lancet Gastroenterol Hepatol. 2018 Jan;3(1):37-46. doi: 10.1016/S2468-1253(17)30290-X. Epub 2017 Oct 4. Lancet Gastroenterol Hepatol. 2018. PMID: 28988687 Clinical Trial.